Resonance Health Applies to Quote 83.3 Million Placement Shares at $0.072 Each

Aakashdeep

06 November 2026 05:25 PM AEDT

Resonance Health Applies to Quote 83.3 Million Placement Shares at $0.072 Each

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Resonance Health Limited (ASX:RHT) has lodged an application for quotation of 83,333,320 ordinary fully paid shares on 6 November 2026, issued at AUD $0.072 per share as part of a placement previously announced to the market on 27 October 2026.

Key Points

83,333,320 ordinary fully paid RHT shares applied for quotation, with an issue date of 6 November 2026
Shares were issued at AUD $0.072 each for cash consideration in Australian dollars
The placement was previously disclosed to ASX via an Appendix 3B lodged on 27 October 2026
Following quotation, total quoted ordinary fully paid shares on issue will be 560,453,553
Unquoted securities include 10,000,000 options expiring 29 June 2029 at $0.095 and 10,888,766 performance rights

Placement Shares Applied for Quotation

Resonance Health Limited lodged an Appendix 2A application with ASX on 6 November 2026, seeking quotation of 83,333,320 ordinary fully paid securities under the ASX code RHT. The filing states that the securities were issued as part of a placement or other type of issue previously notified to the market. The company confirmed in the filing that there are no further issues of securities yet to take place to complete the transaction referred to in the Appendix 3B lodged on 27 October 2026. The securities are being issued for cash consideration denominated in Australian dollars.

Issue Price and Transaction Background

According to the filing, the 83,333,320 new ordinary shares were issued at a price of AUD $0.072 per security. The company's Appendix 2A states that the placement was first announced to the market on 27 October 2026, when an Appendix 3B titled "New - Proposed issue of securities - RHT" was released at 9:57 am on that date. The filing directs readers to the company's disclosures released on 27 October 2026 for further details on the placement, including use of proceeds. No additional details on use of proceeds are contained within the Appendix 2A filing itself.

Issued Capital Following Quotation

Upon quotation of the new securities, the total number of quoted ordinary fully paid RHT shares on issue will be 560,453,553, according to figures disclosed in the filing. In addition to quoted securities, the company's unquoted securities will comprise 10,000,000 options expiring 29 June 2029 with an exercise price of $0.095, listed under the ASX code RHTAC, and 10,888,766 performance rights listed under the code RHTAB. The filing notes that automatically generated capital figures may not reflect the entity's current issued capital if other forms are concurrently being processed by ASX.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.